Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on February 10, 2020. The filing addresses executive compensation adjustments and equity grants approved by the Board of Directors. Note: The request metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as OncoCyte Corporation.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
| Executive Officer | Position | Cash Bonus | Stock Options Granted | Exercise Price |
|---|---|---|---|---|
| Mitchell Levine | Chief Financial Officer | $131,670 | 204,000 | $2.63 |
| Lyndal Hesterberg | Chief Science Officer | $60,000 | 0 | N/A |
Additional Compensation Action: The annual base salary of Mitchell Levine was increased to $356,895.
Material Changes
- Salary Increase: CFO Mitchell Levine received a base salary adjustment effective February 10, 2020.
- Equity Grant: 204,000 stock options were granted to the CFO under the 2018 Equity Incentive Plan.
- CEO Compensation Deferral: The Board deferred a compensation determination for CEO Ronald Andrews until he completes a full year of service (commencing July 1, 2019).
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook. It includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially due to risk factors detailed in the company's Form 10 and other SEC filings. The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the vesting schedule for the 204,000 options granted to the CFO (25% after one year, remainder over 36 months).
- Confirm the total dilution impact of the new option grants relative to the outstanding share count.
- Review the CEO's employment agreement to understand the criteria for the deferred compensation determination.
- Check the company's most recent Form 10-K for the "Risk Factors" referenced in the forward-looking statements disclaimer.